Fluciclovine 18F - Emory University/GE Healthcare/Nihon Medi-Physics

Drug Profile

Fluciclovine 18F - Emory University/GE Healthcare/Nihon Medi-Physics

Alternative Names: 18F-Ge-148; 18F fluciclovine; [18F]-FACBC; Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic-acid; Anti-1-amino-3-F-18-fluorocyclobutane-1-carboxylic-acid; Anti-1-amino-3-fluorine-18-fluorocyclobutane-1-carboxylic acid; Anti-18-F-FACBC; Anti-18F-FABC; Anti-3-18F-FACBC; Anti-F-18-fluorocyclobutane-carboxylic-acid; Axumin; Axumin-PET scan; FACBC; Fluciclovine-F-18; GE-148; Ge-148-18F; Ge-148-F-18; NMK-36; Trans-1-amino-3-18F-fluorocyclobutanecarboxylic-acid

Latest Information Update: 05 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Emory University
  • Developer Blue Earth Diagnostics; Emory University; GE Healthcare; Memorial Sloan-Kettering Cancer Center; Nihon Medi-Physics; University of Arizona; University of Utah
  • Class Amino acids; Carboxylic acids; Cyclobutanes; Imaging agents; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Phase III Glioma
  • Phase II Bone metastases; Brain cancer
  • Clinical Phase Unknown Breast cancer
  • No development reported Head and neck cancer; Lung cancer; Parathyroid cancer

Most Recent Events

  • 25 Jun 2018 Blue Earth Diagnostics enters into a manufacturing and distribution agreement with IASON Sp. z o.o. for fluciclovine 18F in Poland
  • 21 May 2018 Topline results from phase III LOCATE trial released by the Blue Earth Diagnostics
  • 01 May 2018 Phase-II clinical trials in Bone metastases (Diagnosis) in USA (IV) (NCT03496844)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top